+44 20 8123 2220
info@marketpublishers.com

Superoxide Dismutase [Cu-Zn] - Pipeline Review, H1 2020

https://marketpublishers.com/r/S8A5FBBA9B7DEN.html
Date: April 2020
Pages: 72
Price: US$ 3,500.00 (Single User License)
ID: S8A5FBBA9B7DEN

Abstracts

Superoxide Dismutase [Cu-Zn] - Pipeline Review, H1 2020

SUMMARY

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Superoxide Dismutase - Pipeline Review, H1 2020, outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2?) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.

The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers

+44 20 8123 2220
info@marketpublishers.com

products from therapy areas Central Nervous System and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease and Wilson Disease.

Furthermore, this report also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1

+44 20 8123 2220
info@marketpublishers.com

or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

+44 20 8123 2220
info@marketpublishers.com

business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

COMPANIES MENTIONED

AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Apic Bio Inc
AveXis Inc
Biogen Inc
Collaborative Medicinal Development LLC
Priavoid GmbH
Thera Neuropharma Inc
Trucode Gene Repair Inc
Voyager Therapeutics Inc

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Superoxide Dismutase [Cu-Zn] - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/S8A5FBBA9B7DEN.html

Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S8A5FBBA9B7DEN.html